Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Value Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Vanguard Value Index Fund ETF trades at $220.59 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 122.6× Recursion Pharmaceuticals Inc's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| RXRX | VTV | |
|---|---|---|
Market Cap | $2.14B | $262.40B |
Volume | 30,789,535 | 3,293,281 |
Sector | Health | — |
52-Week High | $6.79 | $227.51 |
52-Week Low | $2.84 | $182.86 |
Typical Hold Time | 23 Days | 142 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
VTV trades at $220.59, up 1.09% today, with a bearish technical signal overall despite bullish moving averages. The ETF offers a 2.3% dividend yield and has attracted institutional buying, as seen with QRG Capital Management increasing its stake by 14.7% in Q3 2026. Recent news highlights value stocks outperforming growth in 2026, with VTV leading among Vanguard's large-cap offerings.
The outlook for VTV is supported by the rotation into value stocks and its low 0.03% fee, but risks include underperformance versus the S&P 500 over the long term and sensitivity to interest rate changes. Investor sentiment is mixed, balancing value's resurgence against broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
